As of Apr 24
| -0.32 / -0.83%|
The 1 analysts offering 12-month price forecasts for Anika Therapeutics Inc have a median target of 45.50, with a high estimate of 45.50 and a low estimate of 45.50. The median estimate represents a +18.64% increase from the last price of 38.35.
The current consensus among 1 polled investment analysts is to Buy stock in Anika Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.